LONDON (Alliance News) - Motif Bio PLC said Wednesday it has been given a Notice of Allowance from the US Patent & Trademark Office for use of its antibiotic, iclaprim, to treat bacterial infections.
This notice means that the office intends to grant the patent, which will expire in 2037. Iclaprim is being developed to treat severe infections with methicillin-resistant staphylococcus aureus.
The pharmaceutical company said its patent claims relate to the use of iclaprim to treat staphylococcus aureus infections in cystic fibrosis patients, acute skin infections, and bacterial pneumonia.
"These US patents provide additional exclusivity for iclaprim in the treatment of bacterial infections well into 2037. We are actively building our intellectual property portfolio in the US and other key markets around the globe," said Motif Chief Executive Officer Graham Lumsden.
Shares in Motif Bio were down 0.2% at 29.95 pence on Wednesday.
